MTX2

Across TCGA pan-cancer cohorts, MTX2 RNA differs between tumor and matched normal tissue in 15 of 18 cancer types tested, making tumor–normal expression one of MTX2’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where MTX2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MTX2 is over-expressed in tumor, although a few such as KIRC and KICH show the opposite, repressed pattern.

HNSC, LUAD, and LIHC are the cancer types where MTX2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MTX2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Female	III,IV	+0.768	<.001	12	view →
LUAD	Male	II,III,IV	+0.816	<.001	11	view →
LIHC	Female	II,III,IV	+1.212	<.001	9	view →
STAD	All	II,III,IV	+0.587	<.001	9	view →
LUSC	Female	All	+1.126	<.001	8	view →
BRCA	All	All	+0.523	<.001	6	view →
KIRC	Male	II,III,IV	−0.372	<.001	6	view →
CHOL	All	All	+1.895	<.001	5	view →
KICH	All	All	−0.538	<.001	5	view →
BLCA	All	All	+0.497	.008	4	view →
PAAD	All	All	+0.567	.039	2	view →
ESCA	All	All	+0.681	.006	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 15 lineages.

MTX2–HNSC

Open the HNSC breakdown →